356 related articles for article (PubMed ID: 19670703)
41. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations.
Gjerdrum LM; Woetmann A; Odum N; Hother C; Henrik-Nielsen R; Gniadecki R; Ralfkiaer E
Eur J Haematol; 2008 Jun; 80(6):483-9. PubMed ID: 18331599
[TBL] [Abstract][Full Text] [Related]
42. Type B follicular lymphomatoid papulosis.
Chaudhari PR; Emanuel P; Levitt J
Cutis; 2010 Jun; 85(6):307-11. PubMed ID: 20666192
[TBL] [Abstract][Full Text] [Related]
43. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases.
Kikuchi A; Nishikawa T
Arch Dermatol; 1997 Jul; 133(7):829-33. PubMed ID: 9236520
[TBL] [Abstract][Full Text] [Related]
44. Practical Management of CD30⁺ Lymphoproliferative Disorders.
Hughey LC
Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
[TBL] [Abstract][Full Text] [Related]
45. [Cutaneous neutrophils infiltrates. Case 7. Lymphomatoid papulosis].
Vergier B
Ann Pathol; 2011 Jun; 31(3):198-202. PubMed ID: 21737002
[No Abstract] [Full Text] [Related]
46. Lymphomatoid papulosis type D: a newly described variant easily confused with cutaneous aggressive CD8-positive cytotoxic T-cell lymphoma.
Cardoso J; Duhra P; Thway Y; Calonje E
Am J Dermatopathol; 2012 Oct; 34(7):762-5. PubMed ID: 22688398
[TBL] [Abstract][Full Text] [Related]
47. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
48. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
49. Classification of primary cutaneous large cell lymphomas.
Willemze R; Beljaards RC; Rijlaarsdam U
Dermatol Clin; 1994 Apr; 12(2):361-73. PubMed ID: 8045048
[TBL] [Abstract][Full Text] [Related]
50. Characterization of primary cutaneous CD8+/CD30+ lymphoproliferative disorders.
Martires KJ; Ra S; Abdulla F; Cassarino DS
Am J Dermatopathol; 2015 Nov; 37(11):822-33. PubMed ID: 26485239
[TBL] [Abstract][Full Text] [Related]
51. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin.
Werner B; Massone C; Kerl H; Cerroni L
J Cutan Pathol; 2008 Dec; 35(12):1100-7. PubMed ID: 18616762
[TBL] [Abstract][Full Text] [Related]
52. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
53. CD8+ lymphomatoid papulosis and its differential diagnosis.
Magro CM; Crowson AN; Morrison C; Merati K; Porcu P; Wright ED
Am J Clin Pathol; 2006 Apr; 125(4):490-501. PubMed ID: 16627259
[TBL] [Abstract][Full Text] [Related]
54. Pseudocarcinomatous change in lymphomatoid papulosis and primary cutaneous CD30+ lymphoma: a clinicopathologic and immunohistochemical study of 6 patients.
Scarisbrick JJ; Calonje E; Orchard G; Child FJ; Russell-Jones R
J Am Acad Dermatol; 2001 Feb; 44(2):239-47. PubMed ID: 11174381
[TBL] [Abstract][Full Text] [Related]
55. Acral lymphomatoid papulosis: Report of five cases, differential diagnosis, and review.
Machan S; Juárez Martín Á; Cullen Aravena D; Haro R; Pielasinski Ú; Fuertes L; Córdoba R; Santonja C; Rodríguez-Pinilla SM; Requena L
J Cutan Pathol; 2021 May; 48(5):650-658. PubMed ID: 33269496
[TBL] [Abstract][Full Text] [Related]
56. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule.
Meisenheimer JL
J Drugs Dermatol; 2007 Apr; 6(4):440-2. PubMed ID: 17668543
[TBL] [Abstract][Full Text] [Related]
57. The significance of MUM1/IRF4 protein expression and IRF4 translocation of CD30(+) cutaneous T-cell lymphoproliferative disorders: a study of 53 cases.
Kiran T; Demirkesen C; Eker C; Kumusoglu H; Tuzuner N
Leuk Res; 2013 Apr; 37(4):396-400. PubMed ID: 23332472
[TBL] [Abstract][Full Text] [Related]
58. Apoptosis in CD30-positive lymphoproliferative disorders of the skin.
Greisser J; Doebbeling U; Roos M; Mueller B; Schmid M; Burg G; Kadin ME; Kempf W
Exp Dermatol; 2005 May; 14(5):380-5. PubMed ID: 15854132
[TBL] [Abstract][Full Text] [Related]
59. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
[TBL] [Abstract][Full Text] [Related]
60. [Primary cutaneous CD30+ lymphoproliferative disorders].
Calzado-Villarreal L; Polo-Rodríguez I; Ortiz-Romero PL
Actas Dermosifiliogr; 2010 Mar; 101(2):119-28. PubMed ID: 20223154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
